German China

Business Sense Chiesi Completes Acquisition of Biopharmaceutical Firm Amryt Pharma

Source: Press release Ahlam Rais Reading Time: 1 min

With the takeover of the global, commercial-stage biopharmaceutical company Amryt Pharma, Chiesi will be able to expand its capabilities and develop new treatments to patients living with rare diseases.

Chiesi Farmaceutici recently announced the completion of the acquisition of Amryt Pharma.
Chiesi Farmaceutici recently announced the completion of the acquisition of Amryt Pharma.
(Source: Pixabay)

Parma/Italy – Chiesi Farmaceutici (Chiesi), an international, research-focused biopharmaceuticals and healthcare group, recently announced the completion of the acquisition of Amryt Pharma (Amryt), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing, and commercializing novel treatments for rare diseases.

“We are excited to add the Amryt family to our company in this acquisition that demonstrates our commitment to rare diseases and aligns with our growth strategy through partnerships beyond internal research and development,” said Giacomo Chiesi, head of Chiesi Global Rare Diseases. “Amryt has unique and clinically differentiated products and additional promising drugs in its pipeline, and, as a benefit corporation certified B Corp, Chiesi has a patient-centric and sustainable model in place to make these treatments available to even more patients who need them. As of today, we are officially joining our forces to bring hope to people in need and look forward to this new chapter in our collective journey.”

“This acquisition reflects Chiesi Group’s commitment towards patients. Chiesi strives to create a world where it is common to have a therapy for all diseases and acts as a force for good for society and the planet,” said Giuseppe Accogli, CEO of Chiesi Group. “Amryt Pharma’s team has delivered innovative treatments to rare disease patients with high unmet medical needs. By joining forces and expertise we will be able to grow our capabilities and further strengthen our position to provide a positive impact on patients living with rare diseases.”


Subscribe to the newsletter now

Don't Miss out on Our Best Content

By clicking on „Subscribe to Newsletter“ I agree to the processing and use of my data according to the consent form (please expand for details) and accept the Terms of Use. For more information, please see our Privacy Policy.

Unfold for details of your consent